SVB Wealth LLC Acquires New Position in Roche Holding AG (OTCMKTS:RHHBY)

SVB Wealth LLC acquired a new stake in shares of Roche Holding AG (OTCMKTS:RHHBY) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 15,904 shares of the company’s stock, valued at approximately $555,000.

A number of other institutional investors have also modified their holdings of the business. Brooklyn Investment Group acquired a new stake in Roche in the third quarter worth $40,000. IHT Wealth Management LLC acquired a new stake in Roche in the third quarter worth $236,000. Verity Asset Management Inc. acquired a new stake in Roche in the third quarter worth $253,000. Canopy Partners LLC increased its position in Roche by 4.6% in the third quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock worth $310,000 after buying an additional 344 shares during the period. Finally, Confluence Investment Management LLC increased its position in Roche by 26.3% in the fourth quarter. Confluence Investment Management LLC now owns 13,981 shares of the company’s stock worth $488,000 after buying an additional 2,910 shares during the period.

Roche Stock Performance

RHHBY stock opened at $41.83 on Tuesday. The company has a 50-day simple moving average of $38.38 and a 200 day simple moving average of $38.41. The company has a quick ratio of 0.97, a current ratio of 1.26 and a debt-to-equity ratio of 0.86. Roche Holding AG has a fifty-two week low of $29.20 and a fifty-two week high of $42.43.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on RHHBY shares. Morgan Stanley started coverage on Roche in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Sanford C. Bernstein raised Roche to a “strong-buy” rating in a report on Thursday, January 30th. Finally, UBS Group raised Roche from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.